Vision Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Vision Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.29M	Sell	6,630 -69	-1%	-$30.6K	0.38%	53
2026 Q1	$2.99M	Buy	6,699 +104	+2%	+$48.5K	0.38%	50
2025 Q4	$2.99M	Buy	6,595 +29	+0.4%	+$12.5K	0.36%	50
2025 Q3	$2.57M	Sell	6,566 -306	-4%	-$128K	0.32%	54
2025 Q2	$3.06M	Buy	6,872 +307	+5%	+$141K	0.4%	48
2025 Q1	$3.18M	Buy	6,565 +1,541	+31%	+$718K	0.46%	44
2024 Q4	$2.02M	Sell	5,024 -9	-0.2%	-$4.17K	0.3%	58
2024 Q3	$2.34M	Buy	5,033 +292	+6%	+$140K	0.33%	55
2024 Q2	$2.22M	Buy	+4,741	New	+$2.06M	0.33%	57

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Vision Capital Management's VRTX Position: Q2 2026 in Review

Vision Capital Management reduced its Vertex Pharmaceuticals (VRTX) stake by 1% in Q2 2026, selling an estimated $30.6K and leaving 6,630 shares worth $3.29M. The position accounts for 0.38% of the portfolio, ranked #53.

Vision Capital Management first reported a position in VRTX in Q2 2024 and has held it in 9 quarters since. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Vision Capital Management held 6,630 shares of Vertex Pharmaceuticals worth $3.29M as of Q2 2026.
Vision Capital Management sold 69 Vertex Pharmaceuticals shares in Q2 2026, an estimated $30.6K.
Vertex Pharmaceuticals made up 0.38% of Vision Capital Management's portfolio in Q2 2026, its #53 holding.
Vision Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Vision Capital Management's 13F filing for Q2 2026, filed 10 Aug 2026.